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PRENATAL EXPOSURE TO ENDOCRINE DISRUPTORS:   
A DEVELOPMENTAL ETIOLOGY FOR POLYCYSTIC OVARY SYNDROME 
MEGHAN M. HEWLETT 
ABSTRACT 
 Polycystic ovary syndrome (PCOS) is one of the most common and complex 
endocrinopathies among reproductive-aged women. Symptom heterogeneity among 
clinical cases and in sibling studies suggests that PCOS is a multifactorial disease with 
environmental components. Investigators hypothesize that endocrine disruptors may 
contribute to the pathophysiological origins of PCOS in utero. The goal of this literature 
review is to present and compare the available research investigating the developmental 
origins of PCOS deriving from prenatal exposure to three major classes of endocrine 
disruptors: bisphenol A (BPA), phthalates, and androgenic endocrine disruptors.  
Considerable evidence has been found to suggest links between fetal exposure to 
endocrine disruptors and PCOS. Rodent studies reported that maternal BPA exposure 
dysregulates postnatal development and sexual maturation. In rats, gestational exposure 
to dibutyl phthalate (DBP) and di(2-ethylhexyl)phthalate (DEHP) resulted in polycystic 
ovaries among first and third generation offspring. Additionally, serum DBP 
concentrations are higher among women with PCOS. Regarding DEHP, animal studies 
have shown that prenatal exposure results in an endocrinological profile similar to PCOS. 
Nicotine and 3,4,4’-trichlorocarbanilide (TCC) are known androgenic endocrine 
disruptors. Inducing prenatal exposure to excess androgens in animal models has 
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successfully recreated a PCOS-like phenotype that includes abnormal ovarian function, 
anovulatory cycling, impaired fertility, and increased visceral fat distribution.  
 Based on the literature, endocrine disruptors appear to have an etiological role in 
PCOS development through prenatal exposure and thus may pose one of the greatest 
hazards to fetal health and development.  
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INTRODUCTION 
 
 Polycystic ovary syndrome (PCOS) is a hyperandrogenic and cardiometabolic 
disorder in women. As one of the most common endocrine disorders among women of 
reproductive age, the estimated prevalence of PCOS ranges between 4-12% worldwide 
(Asuncion et al., 2000; Azziz et al., 2004; Chang, 2014; Diamanti-Kandarakis et al., 
1999; Ehrmann, 2005). After excluding for related disorders, the most recently 
established diagnostic criteria suggest that a diagnosis of PCOS includes two of the 
following three criteria: 1.) oligo- or anovulation, 2.) a clinical or biochemical 
observation of hyperandrogenism, and 3.) polycystic ovaries on ultrasonography 
(Rotterdam, 2004). Despite the syndrome’s namesake, a finding of polycystic ovaries is 
no longer required for diagnosis. A large contribution to this change in diagnostic criteria 
came from research which showed that polycystic ovaries were present in about 20% of 
asymptomatic women (Polson, Reed, Scanlon, Quiney, & Franks, 1988). A more recent 
study reported a prevalence of 58% for asymptomatic women presenting with polycystic 
ovaries (Kristensen et al., 2010). Oligo- or anovulation, on the other hand, leads to 
irregular menstruation, amenorrhea, and ovulation-related infertility. Additionally, the 
hormonal imbalance caused by hyperandrogenism generally results in acne and hirsutism. 
Polycystic ovary syndrome is also associated with insulin resistance as well as metabolic 
dysfunction (Apridonidze, Essah, Iuorno, & Nestler, 2005; Dokras et al., 2005). The 
adverse impact of such hormonal and metabolic dysregulation exaggerates the 
syndrome’s clinical presentation and promotes the incidence of chronic sequelae for 
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women in the long term. For example, insulin resistance is associated with a higher risk 
of developing non insulin-dependent diabetes mellitus (NIDDM), hypercholesterolemia, 
and obesity (Strauss & Barbieri, 2014).  Polycystic ovary syndrome is also associated 
with metabolic syndrome (Caserta et al., 2014).  
 
Background 
Luteinizing Hormone Hypersecretion  
The origins of hyperandrogenism in PCOS cases are believed to derive from the 
pituitary hypersecretion of luteinizing hormone (LH). A majority of PCOS cases have 
been shown to have higher serum levels of LH as well as increased frequencies of LH 
pulse secretion (Figure 1) (Balen, 1993; Rebar et al., 1976). As part of normal hormonal 
physiology, ovarian theca cells are stimulated to produce and secrete androgens (mostly 
androstenedione (A) relative to testosterone (T)), which traverse to ovarian granulosa 
cells. In response to pituitary secretion of follicle-stimulating hormone (FSH), granulosa 
cells are stimulated to produce and secrete aromatase which converts the theca-sourced 
androgens to estrogens via aromatization (estrone (E1) and estradiol (E2)) (Figure 1). The 
increase in ovarian androgen production and secretion in PCOS pathophysiology may 
additionally be due to a number of causes which add to the disorder’s complexity such as 
theca cell hypertrophy in response to LH hypersecretion, or an increased expression of 
the LH receptor on theca cells (Jakimiuk, Weitsman, Navab, & Magoffin, 2001). In the 
classical PCOS case, the increase in androgens is due to increased LH which is 
	   3	  
potentiated by either hyperinsulinemia, dysregulated hypothalamic gonadotropin-
releasing hormone (GnRH) secretion, or both.  
 
Hyperinsulinemia 
Insulin resistance and subsequent hyperinsulinemia are common among PCOS 
cases (Dunaif, 1997; Legro, Finegood, & Dunaif, 1998). Hyperinsulinemia has been 
shown to lead to decreased levels of sex hormone-binding globulin (SHBG) and insulin-
like growth factor binding protein – I (IGFBP-I), as well as increases in free androgens 
(Lebovic, Gordon, & Taylor, 2005). While serum concentrations of total insulin-like 
growth factor-I (IGF-I) levels are normal in PCOS cases, decreases in IGFBP-I result in 
increased concentrations of circulating, free IGF-I. In conjunction with insulin-like 
growth factor-II (IGF-II), IGF-I appears to augment the actions of LH-stimulated 
androgen production and secretion in ovarian theca cells. Insulin itself may stimulate 
ovarian androgen production and secretion as well (Barbieri, Makris, & Ryan, 1984; 
Nestler et al., 1998). However, whether it acts directly to stimulate ovarian production 
and secretion at the level of the theca cell or it acts indirectly to stimulate LH secretion at 
the level of the anterior pituitary or both remains to be determined.  
 
Hyperandrogenism 
As previously mentioned, increased LH secretion from the anterior pituitary 
results in theca cell dysfunction. As part of this dysfunction, theca cells produce and 
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secrete high levels of T, A, dehydroepiandrosterone (DHEA), 17-hydroxyprogesterone 
(17-OHP) (Lebovic et al., 2005). The resulting increases in A lead to increased 
production and secretion of E1; however, ovarian E2 secretion is relatively normal 
(Figure 1) (DeVane, Czekala, Judd, & Yen, 1975). Despite normal secretion levels, 
decreased levels of SHBG lead to increased levels of free estrogens, including E2, as well 
as increased levels of free androgens. Hyperandrogenism has been hypothesized to 
contribute to excess LH secretion by lowering the efficacy of feedback inhibition by 
progesterone (P) (Figure 2) (Eagleson et al., 2000). As part of normal physiology, P, 
synergistically with E2, inhibits the pulsatility of GnRH secretion, which subsequently 
inhibits LH secretion. Without this inhibition, GnRH will continue to stimulate LH 
secretion, thereby maintaining this self-perpetuating pathophysiological cycle. 
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Figure 1. Hormonal Levels in Polycystic Ovary Syndrome. Average serum 
concentrations of luteinizing hormone (LH), follicle-stimulating hormone (FSH), estrone 
(E1) and estradiol (E2) were collected among 19 women with polycystic ovary syndrome 
(PCOS) and compared against average serum hormonal concentrations from 10 normal 
women between day 2 and day 4 of their menstrual cycle. Overall, PCOS women had 
significantly higher LH and E1 levels. Adapted from DeVane et al., 1975.
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Figure 2. Pathophysiological Concept of Polycystic Ovary Syndrome (PCOS). 
Luteinizing hormone (LH) hypersecretion stimulates increased production and secretion 
of androgens in ovarian theca cells. While estradiol (E2) secretion is normal, increased 
levels of circulating androgens appear to inhibit negative feedback at the pituitary. 
Increased androgens are also associated with visceral fat deposition, obesity, and 
dyslipidemia. Hyperinsulinemia leads to increased levels of free insulin-like growth 
factor I (IGF-1) which also stimulates ovarian androgen production. Adapted from Chang 
et al., 2014.  
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Ovarian Dysfunction  
Whether the self-perpetuating cycle of excess androgen production at the level of 
the ovary induces PCOS or is an effect of another pathophysiological origin remains to be 
determined. In addition to increased ovarian androgen production, LH hypersecretion 
promotes theca cell hyperplasia and increases the thickness of the ovarian stroma. 
Consequently, these effects prevent the maturation of ovarian follicles (Lebovic et al., 
2005). However, circulating levels of FSH in PCOS sustainably stimulate follicular 
growth. More specifically, preovulatory follicles are constantly recruited to replace atretic 
follicles. However, without proper hormonal stimulation, these follicles fail to complete 
the process of maturation, which normally culminates in ovulation. The clinical result is 
oligo- or anovulation. Increased levels of ovarian androgens may also be a direct cause of 
follicle maturation inhibition (Lebovic et al., 2005).  
 
Clinical Presentation  
Despite the relatively high prevalence of PCOS, the specific pathophysiology is 
complex and remains largely elusive. As a syndrome, PCOS is characterized by variable 
clinical presentations. The redaction of polycystic ovaries as a requisite criterion for 
diagnosis is one reflection of the nonspecific nature of the syndrome’s clinical and 
pathophysiological manifestation (Diamanti-Kandarakis et al., 1999). The initial signs 
and symptoms of PCOS typically present during or just prior to the onset of puberty. 
Indeed, research has shown that the presentation of precocious pubarche as well as 
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adolescent hyperandrogenemia with or without insulin resistance may in fact be a 
manifestation of the syndrome within its early stages (Fruzzetti, Perini, Lazzarini, Parrini, 
& Genazzani, 2009; Ibanez, Lopez-Bermejo, Diaz, Marcos, & de Zegher, 2011; 
McCartney et al., 2006). 
Additionally, the phenotype has been shown to change as a woman progresses 
through life (Hsu, 2013). These dynamic changes over time add to the complexity of this 
syndrome, thereby making a clinical diagnosis difficult to accurately establish and 
complicating prognostic determinations. For example, many disorders have clinical 
presentations that are similar to PCOS such as congenital adrenal hyperplasia, 
hyperprolactinemia, or Cushing’s syndrome (Diamanti-Kandarakis et al., 1999). Such 
difficulties have prompted researchers to look toward finding a cause for PCOS in an 
effort to better understand its pathophysiology and elucidate any potential determinants 
of its development. This effort is comprised of two major objectives: to determine the 
specific point within a woman’s life cycle when PCOS actually begins to develop, and to 
ascertain whether there is a genetic or environmental influence or a combination of both 
that contributes to the biological onset of PCOS. 
 
Biological Onset of Polycystic Ovary Syndrome and Fetal Programming  
Regarding the time point of biological onset, polycystic ovaries and functional 
ovarian hyperandrogenism have been observed in prepubertal girls, which supports the 
hypothesis that the particular origin of PCOS may depend on the establishment of ovarian 
morphology and function at an early stage of development (Battaglia et al., 2002; Siklar, 
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Ocal, Adiyaman, Ergur, & Berberoglu, 2007). More specifically, the developmental 
origin of adult disease during fetal life is believed to stem from fetal programming, a 
process where biological or exogenous signals or insults at critical, and therefore 
susceptible, stages of development induce permanent changes in tissue structure or 
function. These alterations are the manifestation of adaptive responses to such adverse 
signals or insults, and therefore influence the long-term risk of disease. In relation to the 
development of PCOS, a study conducted by Webber et al. (2003) proposed that these 
adaptations take place in utero during ovarian development and oogenesis. By nature, 
these changes in tissue structure or function, which are carried out through fetal 
programming, would not necessarily be observable at birth but may result in altered 
physiological responses later in life as a consequence of these fetal adaptive responses.  
It is well known that the critical developmental stages that take place in utero are 
times of significant cellular proliferation, differentiation, and functional maturation. 
Therefore, intrauterine exposures may have profound effects based not only upon what 
the agent actually is but also upon the timing of exposure, even at low doses. For 
example, it is well known that exposure to insults during the early stages of gestation, 
most notably when organogenesis and differentiation occur, has the potential to cause 
structural defects. On the other hand, adverse prenatal exposures during the later stages of 
gestation (i.e. at the time of fetal maturation) have been shown to lead to functional 
alterations.   
Fetal programming, however, is not solely a pathophysiological event. For 
example, hormonal programming is normally involved in the establishment of sexually 
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dimorphic traits by sex steroids during perinatal development. Studies have demonstrated 
an association between the surge of sex steroid secretion that takes place during this 
process and the neuroanatomical as well as functional changes in the forebrain (Simerly, 
2002). This process was also associated with the changes in the expression of steroid-
metabolizing enzymes in the liver and the development of sexual behavior (Collaer & 
Hines, 1995; Hutchison, 1997). 
However, just as low nutrient or oxygen supply can significantly alter anabolic 
and catabolic homeostasis, suboptimal intrauterine conditions brought upon by exposure 
to adverse exogenous agents have been proposed to induce programming adaptions, and 
thus influence the development of disease in adult life. For example, fetal exposure to an 
excess of glucocorticoids, in conjunction with an adverse intrauterine environment 
caused by inadequate maternal nutrition, may result in physiological programming and 
ultimately lead to impaired fetal growth and cardiometabolic disease later in life (Harris 
& Seckl, 2011; Seckl, 2008). 
Additional findings in support of this hypothesis derive from animal studies, 
which have shown that experimentally induced androgen excess during fetal 
development, may lead to both reproductive and metabolic abnormalities in later life 
similar to those exhibited in women with PCOS. For example, studies using the rhesus 
monkey as an animal model have shown that fetal exposure to very high levels of 
exogenous androgens in maternal circulation eventually results in many of the 
characteristic features of PCOS when the female offspring reach adolescence (Dumesic, 
Abbott, Eisner, & Goy, 1997; Eisner, Barnett, Dumesic, & Abbott, 2002; Eisner, 
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Dumesic, Kemnitz, Colman, & Abbott, 2003). Such features include disordered ovarian 
function, delayed menarche, irregular anovulatory cycles, and thus impaired fertility. As 
adults, the female rhesus monkeys developed enlarged ovaries with a number of 
moderately-sized antral follicles (Eisner et al., 2002). Endocrine dysregulation was 
another prominent feature with hypersecretion of LH resulting from increased ovarian 
and adrenal androgen secretion as well as insulin resistance (Abbott, Tarantal, & 
Dumesic, 2009).  
Findings from these studies additionally hypothesize that prenatal androgenization 
of female rhesus monkeys may promote alterations in the distribution of adipose tissue. 
Investigators observed a preferential accumulation of abdominal and visceral fat as the 
offspring reached adulthood, which were independent of obesity and reflected a relatively 
masculine distribution (Eisner et al., 2003). Excess androgen also appeared to 
differentially alter the secretion of insulin and its action on tissues depending on the 
timing of exposure during gestation (Eisner, Dumesic, Kemnitz, & Abbott, 2000). More 
specifically, fetal androgenization during early gestation led to impaired pancreatic beta 
cell function, while the same exposure during late gestation altered insulin sensitivity 
(Eisner et al., 2000). Other studies conducted in male monkeys have demonstrated similar 
effects on glucose-insulin homeostasis (Varlamov et al., 2012).  
The alterations in visceral fat accumulation as well as the changes in insulin 
secretion have been hypothesized by investigators as potential contributors to the 
pathophysiological development of insulin resistance (Xita & Tsatsoulis, 2010). More 
specifically, visceral adiposity, also known as central obesity, has been associated with 
	   12	  
insulin resistance (Tosi et al., 2015). Therefore, alterations in fetal programming from 
androgen excess may result in impaired insulin secretion. A study conducted by Bruns et 
al. (2004) proposed that this programming occurs at the level of potassium-dependent 
adenosine triphosphate (ATP) channels on the surface of pancreatic beta cells. Such 
programming would impair pancreatic beta cell response to glucose, thereby hampering 
insulin secretion. Taken together, impairment in insulin secretion from impaired beta cell 
function and insulin resistance increase the likelihood of developing NIDDM in 
adulthood (Bruns et al., 2004). This synergy of metabolic dysfunction has been shown to 
lead to the premature onset of NIDDM in women with PCOS (Book & Dunaif, 1999; 
Dunaif, 1993; Dunaif & Finegood, 1996). Findings from animal studies in male rhesus 
monkeys also suggest that programming takes place during fetal development, as 
prenatally androgenized male offspring did not continue to have elevated levels of 
androgens into adulthood (Bruns et al., 2004). 
Many studies provide support for the developmental origin hypothesis of PCOS. 
A majority of these studies propose that a particular subset of PCOS development in adult 
life is mediated through intrauterine exposure, and ultimately induces its metabolic and 
reproductive sequelae (Abbott, Barnett, Bruns, & Dumesic, 2005). At the level of the 
ovary, studies conducted in prenatally androgenized ewes have reported that such 
exposure influences early ovarian follicular development (Forsdike et al., 2007). A 
notable characteristic of a significant proportion of PCOS cases is polycystic ovaries, 
which present with a disordered pattern of folliculogenesis. Correspondingly, exogenous 
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androgens have also been shown to affect ovarian follicular development in the rhesus 
monkey (Vendola et al., 1999).  
Additional ovarian features that can present in women with polycystic ovaries are 
an increased number of antral follicles. However, women with anovulatory cycles may 
actually exhibit halted antral follicle development (Franks, Mason, & Willis, 2000). 
Studies have also shown that early preantral follicle development can be disturbed in 
polycystic ovaries. In a study conducted by Webber et al. (2003), small preantral follicle 
density was significantly higher in ovarian tissue samples from anovulatory women with 
polycystic ovaries than in tissues collected from participants with normal ovaries. The 
proportion of follicles for both ovulatory and anovulatory polycystic ovary tissue 
collections at different stages of early growth differed from normal collections. More 
specifically, women with polycystic ovaries had a relatively smaller proportion of 
primordial follicles and a higher proportion of primary follicles (Webber et al., 2003). 
Studies have investigated the interplay of anti-müllerian hormone (AMH) in this 
observation. Anti-müllerian hormone is known to exert different effects in different 
tissues and at different points in the human life cycle. For example, AMH plays an 
important role in the development and sexual differentiation of the male fetus. More 
specifically, AMH is secreted from sertoli cells and inhibits the development of mullerian 
ducts, which takes place during female fetal development. This inhibition gives rise to the 
wolffian duct system and the process of male development proceeds (Behringer, 
Finegold, & Cate, 1994). However, AMH has been shown to have an influence in female 
reproductive development and physiology, particularly during folliculogenesis. At around 
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the fifth month of gestation, the female fetal ovary possesses several million primordial 
follicles each containing a primary oocyte (Wallace & Kelsey, 2010). At the time of 
menarche, the first few follicles will begin the process of folliculogenesis in which 
multiple stages of follicular growth occur. Many primordial follicles will not complete 
this process and will ultimately undergo apoptosis. However, the follicles that evade cell 
death will successfully develop into primary follicles, followed by secondary follicles, 
and finally tertiary follicles. Tertiary follicle development is the final stage before 
ovulation and includes the development of a fluid-filled cavity known as an antrum. The 
granulosa cells of primordial follicles steadily secrete AMH; however, secretion increases 
as the follicle begins folliculogenesis. Secretion reaches a maximum when the follicle 
begins to develop an antrum and then subsequently diminishes (Andersen & Byskov, 
2006; Durlinger, Visser, & Themmen, 2002).  
Folliculogenesis is a dynamic growth process, thus the ovary will possess multiple 
follicles that are at different stages of development. This pattern of secretion and the 
overall serum level of AMH have been identified as useful biomarkers because they are 
associated with the number of antral follicles (i.e. tertiary follicles) present within the 
ovaries (Fanchin et al., 2003; Muttukrishna et al., 2005; van Rooij et al., 2004). Anatomic 
investigations of polycystic ovaries have shown that the number of preantral and small 
antral follicles can be up to six times greater compared to the number of the same 
follicles in normal ovaries (Webber et al., 2003). Correspondingly, women with PCOS 
have been found to have higher serum concentrations of AMH compared to women 
possessing normal ovaries (Homburg & Crawford, 2014; Homburg et al., 2013). 
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Additionally, while the rate of folliculogenesis is constant among follicles within normal 
ovaries, follicles of polycystic ovaries appear to develop at an accelerated rate as there 
are a higher proportion of follicles in the later stages of development (i.e. preantral and 
small antral follicles) (X. Huang, Liu, & Wang, 2007). Studies conducted in rats have 
also shown that offspring that had fetal exposure to excess androgens had a higher 
density of preantral and antral ovarian follicles compared to offspring that were not 
exposed (Tehrani, Noroozzadeh, Zahediasl, Piryaei, & Azizi, 2014). Furthermore, a study 
conducted in sheep showed that prenatal T exposure increased the secretion of AMH 
from antral follicles (Veiga-Lopez, Ye, & Padmanabhan, 2012). Such findings indicate 
that the increased level of serum AMH and the associated increase in the number of 
preantral and antral follicles could be the result of altered fetal programming.  
 
Association of Environmental Factors with PCOS 
PCOS has been observed to be familial in a large proportion of clinical cases; 
however, investigations of potential genetic polymorphisms or aberrations have not yet 
produced consistent findings (Homburg & Crawford, 2014). Additionally, an increased 
prevalence of PCOS has been identified in populations where genetic variability has 
remained relatively constant (Diamanti-Kandarakis et al., 1999). While many clinical and 
scientific findings also contribute to the hypothesis that environmental exposure plays a 
role in the etiology of PCOS, investigators have not ruled out the involvement of genetic 
inheritance. As described previously, numerous studies have been able to successfully 
replicate a permanent, PCOS-like phenotype in animal models through exogenous 
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exposure to excess androgens. However, other studies have demonstrated an increased 
prevalence of PCOS in women with congenital adrenal hyperplasia due to a 21-
hyrdroxylase deficiency (Dumesic, Goodarzi, Chazenbalk, & Abbott, 2014). Starting the 
third month of fetal life, this genetic defect results in increased androgen production and 
ultimately increased levels of free androgens in a manner not unlike the exogenous 
administrations employed in the animal studies (White & Speiser, 2000; Xita & 
Tsatsoulis, 2006).  
From a developmental perspective, environmental exposure could contribute to 
the altered fetal programming hypothesis as a potential modifier of the phenotypic 
expression of PCOS later on in life. Thus, environmental exposures could possibly act as 
determinants for symptom severity. More specifically, environmental exposures could 
potentially explain the significant variability of symptom severity and clinical 
presentation observed among women with PCOS. When genetic traits are also taken into 
consideration, environmental exposures may actually increase the risk of a manifestation 
of the PCOS phenotype among women who are potentially genetically predisposed 
(Diamanti-Kandarakis, Christakou, & Marinakis, 2012). 
 
Endocrine Disruptors 
It is well known that exposure to developmental hazards is prevalent within the 
modern living environment. One of the most concerning agents are endocrine disrupting 
chemicals, otherwise known as endocrine disruptors. As the name implies, endocrine 
disruptors are defined by the Environmental Protection Agency (EPA) as “exogenous 
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agents that disturb the synthesis, secretion, metabolism, binding action, or metabolism of 
natural blood-borne hormones that are responsible for homeostasis, reproduction, and 
developmental processes” (Diamanti-Kandarakis et al., 2009). Endocrine disruptors can 
be natural or man-made substances. Such examples include pharmaceuticals, dioxin and 
dioxin-like compounds, polychlorinated biphenyls (PCBs), pesticides such as 
dichlorodiphenyltrichloroethane (DDT), and plasticizers such as bisphenol A (BPA). Due 
to their widespread prevalence in a number of materials, endocrine disruptors are present 
in many consumer products including plastic bottles, metal food cans, detergents, food, 
toys, and cosmetics.  
Concern over endocrine disruptors as a health hazard has increased as research 
findings have shown that endocrine disruptors may pose the greatest risk during prenatal 
development (Schug, Janesick, Blumberg, & Heindel, 2011). As this is a time of 
significant organ and neural system development, it is one of the most susceptible periods 
of human growth. To add to this susceptibility, protective measures such as DNA repair, 
an adequate immune system, detoxifying enzymes, and the blood/brain barrier are not 
fully developed in the fetus (Newbold, Padilla-Banks, Snyder, Phillips, & Jefferson, 
2007). The higher metabolic rate relative to adults may also render the fetus susceptible 
to developmental toxicity (Newbold et al., 2007). Furthermore, such exposure during a 
critical period of development has been proposed to result in irreversible changes to 
differentiating tissue, not excluding the brain (Bigsby et al., 1999). For example, a 
longitudinal cohort study of prenatal exposure to polybrominated diethyl ethers (PBDEs), 
a common flame retardant compound, found that children with higher levels of prenatal 
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exposure scored lower on mental and psychological developmental assessment tests 
compared to children with low levels of prenatal PBDE exposure (Bigsby et al., 1999). 
Numerous studies report similar adverse effects including behavioral deficits in 
association with prenatal exposure to pesticides, especially organophosphates (OPs) 
(Gonzalez-Alzaga et al., 2014).  
In addition to lower intelligence quotients, children with relatively higher levels 
of prenatal exposure to PCBs had a higher incidence of neuromuscular and 
neurodevelopmental delay within the first 24 hours of life compared to children with 
average levels of prenatal exposure (Jacobson & Jacobson, 1996). Research findings also 
propose that endocrine disruptors interfere with fetal adipocyte development, thereby 
increasing the risk of obesity and metabolic disorders later in life (Ashley-Martin et al., 
2014).  
Prospective cohort analyses have shown that the effects of prenatal BPA and 
phthalate exposure on metabolic function appear to be sex-specific (Ashley-Martin et al., 
2014; Chou et al., 2011). A longitudinal birth cohort study conducted in Canadian 
mothers reported an inverse relationship between maternal exposure to BPA during the 
first trimester. The study also reported an inverse relationship between this exposure and 
umbilical cord blood levels of adiponectin among male infants as well as a markedly 
elevated risk of high levels of leptin in umbilical cord blood among male infants with 
moderate to high levels of maternal mono (3-carboxypropyl) phthalate (MCPP) exposure 
(Ashley-Martin et al., 2014). Another prospective study conducted in a Taiwanese birth 
cohort found that maternal exposure to BPA was associated with increased odds of low 
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adiponectin levels in male infants, but decreased odds in female infants (Chou et al., 
2011). However, both low and high levels of maternal BPA exposure were associated 
with high leptin levels in female infants (Chou et al., 2011). Additionally, increased 
levels of maternal BPA exposure were associated with higher odds of significantly 
elevated umbilical cord blood leptin levels in both male and female infants (Chou et al., 
2011).  
As studies have shown that low as well as high levels of both of adiponectin and 
leptin are associated with potentially adverse outcomes, these results illustrate the 
potential impact of intrauterine exposure on the regulation and function of fetal 
metabolism (Karakosta et al., 2011; Romano, Savitz, & Braun, 2014; Walsh, Byrne, 
Mahony, Foley, & McAuliffe, 2014). Both leptin and adiponectin are integral to the 
metabolic process. Leptin is a hormone secreted by adipocytes to signal satiety to the 
brain and inhibit feeding behavior. As a part of normal metabolic homeostasis and fat 
storage regulation, leptin levels typically remain stable, but are also known to increase 
with age (Balasko, Soos, Szekely, & Petervari, 2014; Li, Matheny, Nicolson, Tumer, & 
Scarpace, 1997). As elevated leptin levels correlate with obesity, high leptin levels at 
birth could be associated with obesity and its comorbidities later in life such as NIDDM. 
The protein adiponectin, on the other hand, regulates glucose levels as well as fatty acid 
metabolism. As adiponectin levels are highest at birth, lower levels during this time 
appear to be associated with an increased risk of metabolic dysfunction in adulthood 
(Mazaki-Tovi, Kanety, & Sivan, 2005).  
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Endocrine disruptors can also interfere with cyclic processes regulated by 
endogenous hormones, including female reproductive function. The female reproductive 
system is highly susceptible to perturbation as normal function greatly relies upon the 
finely controlled modulation of ovarian steroidogenesis in order to properly execute 
folliculogenesis and ovulation. As endocrine disruptors are ubiquitous in nature as well as 
in man-made products, the opportunities of perturbing this sensitive system are extensive. 
Research shows that exposing the female reproductive system to commonly encountered 
endocrine disruptors such as PCBs can alter the menstrual cycle (Cooper, Klebanoff, 
Promislow, Brock, & Longnecker, 2005). Pesticides are a subgroup of reproductive 
endocrine disruptors reported to exert a variety of effects. A cohort study conducted in 
female agricultural workers showed that women with occupational exposure to pesticides 
with suspected hormonal activity had 60 to 100% increased odds of experiencing 
prolonged menstrual cycles, missed periods, as well as inter-menstrual bleeding 
compared to women without occupational exposure (Farr, Cooper, Cai, Savitz, & 
Sandler, 2004). A study conducted in the same cohort found an association between these 
symptoms and infertility (Rowland et al., 2002).  
Given the altering effects of endocrine disruptors on developmental, metabolic, 
and reproductive processes, such exogenous agents could potentially be involved in the 
development of PCOS. Accordingly, an increasing body of research shows that endocrine 
disruptors may impact fetal development by altering fetal programming thereby inducing 
the development of PCOS later on in life.  
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Specific Aims  
This literature review will present and compare the available research on 
individual endocrine disruptors and their pathophysiological roles in the development of 
PCOS. As such, this investigation will include studies and experimental approaches that 
specifically focus on the developmental effects of exposure to endocrine disruptors 
during fetal life.  
This discussion will proceed with a comprehensive analysis of fetal exposure to 
three major classes of endocrine disruptors: BPA, phthalates, and endocrine disruptors 
with androgenic activity. Compared to other endocrine disruptors, the agents selected for 
this review have been the most extensively studied in regard to the relationship between 
fetal exposure and the development of PCOS later in life. Data on exposure assessment 
for each endocrine disruptor will be detailed to include their major sources of contact, the 
media and microenvironments in which they reside, their primary routes of exposure, as 
well as preliminary research that prompted investigators to assess their involvement in 
the fetal origins of PCOS. Examinations of each individual endocrine disruptor will 
conclude with an overall evaluation of the current standing of the research and will 
provide recommendations for further studies ascertaining its role in the etiology of 
PCOS. In an effort to elucidate the current and emerging findings related to this area of 
study as a whole, this review will discuss the challenges encountered and reported in the 
published research and propose future directions modeled after novel research 
methodologies that show promise for further investigation. 
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In summary, this literature review will aim to determine the potential impact of 
endocrine disruptors on fetal programming through a discussion of the available literature 
investigating the developmental origins of PCOS deriving from fetal exposure to three 
major classes of endocrine disruptors. This report will therefore serve to inform 
investigators about current findings and provide recommendations for future studies.
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PUBLISHED STUDIES 	  
Bisphenol A  
Bisphenol A is a man-made chemical substance largely used in the making of 
polycarbonate plastics and epoxy resins. Polycarbonate plastics are used to make a 
multitude of consumer goods including plastic water bottles and baby bottles, impact-
resistant safety equipment, and medical devices. Epoxy resins are often applied to metal 
products such as food cans, bottle caps, and water supply pipes (National Toxicology 
Program, 2010). Additionally, BPA has also been detected in a number of thermal paper 
products such as cash register and ATM receipts, as well as in certain dental composites 
and sealants. Findings from the 2003-2004 National Health and Nutrition Examination 
Survey (NHANES) conducted by the Centers for Disease Control (CDC) reported that 
93% of Americans aged six years or older had detectable urinary levels of BPA (Lakind 
& Naiman, 2008). Accordingly, human exposure to BPA is considered to be ubiquitous. 
The high prevalence of BPA body burden in human populations is explained by 
the facility with which BPA enters the body. BPA largely comes from dietary sources, 
thus the major route of exposure is through ingestion of contaminated food and liquids 
(National Toxicology Program, 2010). Several in vivo studies have found that the effects 
of BPA exposure are significant. For example, BPA has been shown to act in these 
studies as an estrogen agonist as well as an estrogen antagonist (Alonso-Magdalena, 
Morimoto, Ripoll, Fuentes, & Nadal, 2006; Melzer et al., 2011; Steinmetz, Brown, Allen, 
Bigsby, & Ben-Jonathan, 1997; Susiarjo, Hassold, Freeman, & Hunt, 2007). In vivo 
studies have additionally demonstrated that BPA acts as an androgen and thyroid 
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hormone antagonist (Fini et al., 2007; Lee, Chattopadhyay, Gong, Ahn, & Lee, 2003; 
Takahashi & Oishi, 2001).  
Currently, BPA has been reported to be present at safe levels in consumption 
products; however, due to its estrogenic activity, it has been identified as a possible 
hazard to fetal development (United States Food and Drug Administration, 2010). While 
the placenta confers a protective barrier against the transmission of infectious agents, the 
fetus may still be susceptible to BPA bioaccumulation during the first half of fetal 
development. Indeed, BPA has been identified in fetal serum and full-term amniotic 
fluid, confirming passage through the placenta (Ikezuki, Tsutsumi, Takai, Kamei, & 
Taketani, 2002). Additionally, the BPA concentration in amniotic fluid assayed at 15 to 
18 weeks gestation was found to be five times higher than maternal serum samples 
collected during early pregnancy, as well as maternal serum samples collected during late 
pregnancy (Ikezuki et al., 2002). While the precise mechanism of the metabolic clearance 
of BPA is unknown, BPA likely accumulates in amniotic fluid into mid-term gestation 
due to the immature liver function of the fetus, thus subjecting it to significant exposure. 
However, amniotic fluid concentrations of BPA were observed to decrease as fetuses 
reached full term, possibly indicating that the fetus gradually metabolized BPA as liver 
functionality matured (Ikezuki et al., 2002). 
While exposure may diminish over the second half of fetal life, rodent studies 
report that prenatal BPA exposure nonetheless leads to morphological and physiological 
alterations of the reproductive system (Table 1). For example, BPA administered during 
pregnancy at doses typically encountered in the environment passes on to fetuses and has 
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been shown to alter postnatal development as well as sexual maturation (Howdeshell, 
Hotchkiss, Thayer, Vandenbergh, & vom Saal, 1999). Another study investigating in 
utero exposure of BPA in rodents found that exposure during early ovarian development 
resulted in decreased fertility among the first generation (F1) offspring (Wang, Hafner, & 
Flaws, 2014). Such exposure has also been proposed to span across generations as 
impaired oocyte meiotic maturation has also been reported to occur (Lawson et al., 2011; 
Susiarjo et al., 2007).  
As BPA has been associated with both metabolic and reproductive dysregulation, 
researchers have begun to investigate its potential contribution to the development of 
PCOS, a condition known for its presentation of metabolic and reproductive aberrations. 
Experimental studies in women found that serum BPA concentrations in those diagnosed 
with PCOS were significantly higher compared to women without PCOS (Kandaraki et 
al., 2011; T. Takeuchi & Tsutsumi, 2002). Additionally, serum BPA levels positively 
correlated with BMI, total T, and free T for both women with and without PCOS; 
however, no such correlation between serum BPA and any other sex hormone-related 
concentrations was found (Kandaraki et al., 2011; T. Takeuchi & Tsutsumi, 2002; Toru 
Takeuchi, Tsutsumi, Ikezuki, Takai, & Taketani, 2004). Studies have also reported a 
positive correlation between BPA levels and the severity of insulin resistance in women 
with and without PCOS (Kandaraki et al., 2011; Tarantino et al., 2013). More 
specifically, women with PCOS were found to have higher serum BPA concentration 
levels along with more severe cases of insulin resistance compared to women without 
PCOS (Tarantino et al., 2013). Increased insulin resistance has been reported to be 
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prevalent among PCOS cases as it is present in a majority of obese women and up to 30% 
of non-obese women with the syndrome (Awwad & Abiad, 2013; Rajkhowa, Bicknell, 
Jones, & Clayton, 1994).  
Findings from studies conducted at the level of neonatal exposure have 
demonstrated effects similar to those conducted solely at the level of prenatal exposure. 
For example, results from mouse models have proposed that neonatal exposure to BPA 
may also be involved in the pathogenesis of insulin resistance as it is associated with 
alterations in glucose metabolism and insulin secretion (Alonso-Magdalena et al., 2006). 
Neonatal exposure to BPA in rats has been shown to exert endocrine and reproductive 
alterations in a manner similar to PCOS. A study conducted by Fernández et al. (2010) 
found that, in comparison to controls, newborn rats injected with BPA from postnatal day 
1 to postnatal day 10 at doses lower than the Lowest Observed Adverse Effect Level 
(LOAEL) established by the EPA had higher serum T and E2 levels, but decreased serum 
P levels. When examined at the level of hypothalamic/pituitary secretion, these levels of 
BPA were also associated with alterations in GnRH secretion. Investigators from 
previous studies have suggested that abnormal levels of serum sex hormone 
concentrations could dysregulate the pulsatility pattern of GnRH secretion (Marshall, 
Eagleson, & McCartney, 2001). Correspondingly, the time intervals between GnRH pulse 
secretions in neonatally exposed rats at levels below the LOAEL were decreased 
compared to controls (Fernandez, Bianchi, Lux-Lantos, & Libertun, 2009; Fernandez et 
al., 2010).  
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Reduced time between pulses indicates that the frequency of GnRH secretions, as 
well as downstream hormone secretions regulated by GnRH such as LH and FSH, has 
increased. Rats exposed at these low levels were also found to be subfertile as they 
subsequently had fewer offspring compared to controls (Fernandez et al., 2010). Rats that 
received BPA doses at two times the No Adverse Effect Level (NOAEL) defined by the 
EPA were also found to have these effects as well as a significant number of cystic 
ovarian follicles (Fernandez et al., 2010). The alterations in fertility at this dosage level of 
neonatal exposure in rats, however, were much more significant as they did not ovulate or 
go on to produce any offspring (Fernandez et al., 2010). These alterations produced at the 
hypothalamic-pituitary unit as well as the ovarian level resemble the dysregulation 
observed in PCOS cases. The pulsatile frequency of GnRH/LH secretion has been 
observed to be increased in PCOS (Marshall et al., 2001). As LH acts to support ovarian 
theca cells, which secrete androgens, this increased pulsatility has been proposed as a 
potential cause for elevated serum T levels seen in both animal studies and in PCOS 
cases (Fernandez et al., 2010). Regarding a more direct mechanism induced by exposure, 
it has been hypothesized that BPA acts to dysregulate 17 beta-hydroxylase, an enzyme 
involved in ovarian steroid biosynthesis, thereby resulting in androgen overproduction at 
the level of the ovary and thus contributing to the development of PCOS (Barrett & 
Sobolewski, 2014; Diamanti-Kandarakis et al., 2012). However, for many chemical 
hazards, the time of exposure that poses the greatest risk to health and future 
development is during the prenatal period when organ systems and physiological 
homeostasis are being established (Table 1). For example, prenatal, not neonatal, 
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exposure of female rats to NOAEL concentrations of BPA were observed to have a 
greater percentage of relatively longer estrous cycles compared to controls (Schonfelder, 
Friedrich, Paul, & Chahoud, 2004). Additionally mouse studies of prenatal exposure at 
levels far less than the NOAEL for BPA found that female offspring had a significantly 
earlier onset of puberty (Honma et al., 2002; Howdeshell et al., 1999).   
While the findings from animal studies appear to correlate with the research on 
adult BPA exposure and the incidence of PCOS, the effects of human prenatal exposure 
to BPA remain largely unknown. As of this review, no human studies of prenatal BPA 
exposure have been published to longitudinally investigate its potential association with 
PCOS development during adolescence or adulthood. However, studies of other 
endocrine disrupting chemicals have shown that those with estrogenic activity may affect 
the development of estrogen-sensitive organs (Nguyen et al., 2011). Taking into account 
the findings from animal studies that indicate that BPA impacts prenatal programming 
and thus leads to alterations in endocrine and reproductive function, future research 
should longitudinally examine the relationship between in utero exposure in humans and 
the development of PCOS. As one approach, investigators could utilize developmental 
biomarkers, particularly those involved in reproductive development, to explore this 
association in female infants and children in a longitudinal cohort (Barrett & Sobolewski, 
2014).
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Table 1. Reported Effects of Prenatal Exposure to Bisphenol A (BPA) in Rodent 
Models. The effects of BPA exposure during fetal development vary by dosage in 
micrograms or milligrams per kilogram per day (µg/kg/day or mg/kg/day) and prenatal 
developmental stage of exposure. Reported reasoning for dosage and timing of exposure 
are listed, as available. *Exposure measured over multiple lengths of time. Results apply 
to all durations of BPA exposure.  
 
Species Developmental Stage of Exposure Dosage Effects Reference 
Mouse Day 11-17 (Organogenesis) 
2.4 µg per kg/day 
(environmentally 
relevant) 
Advanced onset of 
first estrous 
Howdeshell et al., 
1999 
Mouse 
Day 11-Birth 
(Ovarian 
Development) 
0.5 µg per kg/day 
(Mimics exposure 
from bottle feeding) 
 
Decreased number of 
primordial follicles 
 
Shortened estrous 
period 
 
Decreased fertility 
(Impaired Ovulation) 
Wang et al., 2014 
20 µg per kg/day 
(Previously shown to 
disrupt oocyte 
meiosis) 
 
Decreased number of 
primordial follicles 
 
Shortened estrous 
period 
 
Decreased fertility 
(Impaired Ovulation) 
50 µg per kg/day 
(EPA referenced safe 
dose) 
Decreased number of 
primordial follicles 
 
Advanced puberty 
onset 
 
Decreased fertility 
(Impaired Gestation) 
Mouse 
Day 11.5-18.5 
(Oocyte 
Maturation) 
20 µg per kg/day 
Increased incidence 
of meiotic aberrations 
in oocytes 
Susiarjo et al., 
2007 
Mouse Day 11-12, 12.5, 13.5, and 14.5 20 µg per kg/day 
Changes in oocyte 
gene expression 
within 24 hours of 
exposure onset 
 
Increased incidence 
of meiotic aberrations 
in oocytes 
Lawson et al., 
2011* 
Rat Day 6-21 50 mg per kg/day (NOAEL) Longer estrous cycles 
Schönfelder et al., 
2004 
Mouse Day 11-17 20 µg per kg/day Advanced onset of first estrous Honma et al. 2002 
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Phthalates  
Phthalates are used to provide flexibility and soften numerous materials such as 
plastic and vinyl (Heudorf, Mersch-Sundermann, & Angerer, 2007). They can be widely 
found in numerous consumer products such as cosmetics, toiletries, shower curtains, 
wallpaper, as well as food packaging (Heudorf et al., 2007). Additionally, phthalates are 
used to manufacture a number of industrial products such as solvents, insecticides, 
building materials, adhesives and detergents (Heudorf et al., 2007). Phthalates are easily 
released into the air and water as part of the manufacturing process (Bertelsen et al., 
2013). They are also released into the same environmental media as well as food sources 
when consumers use products that contain them (Heudorf et al., 2007). Regarding dietary 
exposure, foods with relatively higher fat content such as dairy products and meats have 
been found to be a major food source (Fromme et al., 2007). Inhalation of household dust 
contaminated with phthalates is another route of exposure (Heudorf et al., 2007). The 
prevalence of phthalate exposure is considered to be widespread in the United States as 
most people in the general population have been found to have detectable urine levels of 
phthalate metabolites (Crinnion, 2010). In rodent studies, phthalate exposure has been 
found to be associated with adverse metabolic and reproductive effects such as increased 
visceral adiposity and reduced fertility (X. F. Huang et al., 2012; Schmidt, Schaedlich, 
Fiandanese, Pocar, & Fischer, 2012). Studies also indicate that the developing fetus is 
vulnerable to phthalate exposure as these chemicals are able to cross the placental barrier 
(Hart et al., 2014). Additionally, an increased incidence of pubertal abnormalities have 
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been detected in up to three generations following fetal phthalate exposure (Manikkam, 
Tracey, Guerrero-Bosagna, & Skinner, 2013).  
Given that the effects of phthalate exposure are similar to the symptoms seen in 
PCOS, investigators have begun to examine the potential association between fetal 
phthalate exposure and the development of PCOS. The current literature has reported 
limited findings on the following exposures: dibutyl phthalate (DBP) and di(2-
ethylhexyl) phthalate (DEHP). 
 
Dibutyl Phthalate  
 Dibutyl phthalate is primarily used as a plasticizing agent to increase plastic 
flexibility. DBP is also commonly found in cosmetics and dye solvents such as printing 
inks. On average about 95% of people are exposed to less than 10 micrograms of DBP 
per kilogram of bodyweight per day (µg/kg/day) (Kohn et al., 2000). Interestingly, DBP 
levels were found to differ among age groups and between sexes as reproductive-aged 
women were found to have the highest levels of DBP urine metabolites (Blount et al., 
2000). Investigators have proposed that the higher level of exposure among this group 
may be due to more frequent usage of personal care products containing DBP such as nail 
polish, perfume, and hair spray (Blount et al., 2000). Studies of high-level DBP exposure 
in rodents have shown that exposure during pregnancy was associated with reproductive 
system and organ abnormalities in female offspring (National Toxicology, 2003). 
Additionally, findings from animal studies indicate that rodents are more susceptible to 
the adverse reproductive effects of DBP when they are exposed during prenatal 
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development compared to adult exposure (National Toxicology, 2003). A study in rats 
gestationally exposed to plastic-derived phthalates (DBP and DEHP) as well as BPA 
conducted by Manikkam and colleagues (2013) found that all of the females among the 
F1 and third generation (F3) offspring had a significantly higher incidence of polycystic 
ovaries (Figure 2). 
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Figure 3. Incidence of Polycystic Ovaries among Rats with Control, Plastics, or 
Lower Dose (LD) Plastics Lineages. Percentages of first (F1) and third (F3) generation 
offspring arising from ancestral lineages prenatally exposed to plastics derived endocrine 
disruptors (BPA, DEHP, and DBP) compared to ancestral rats without prenatal exposure 
(Control). The actual number of rats with polycystic ovaries/total number of rats in each 
group is shown above each respective bar graph. Ancestral gravid rats designated as 
“Plastics” received intraperitoneal injections of BPA, DEHP, and DBP at 50 mg/kg/day, 
750 mg/kg/day, and 66 mg/kg/day, respectively over embryonic day 8-14 of gestation. 
Ancestral gravid rats designated as “LD Plastics” were exposed over the same period of 
gestation as “Plastics” rats, but at half the original dose for each endocrine disruptor. 
***p < 0.001. Taken from Manikkam et al., 2013.  
 
 Conversely, F1 and F3 rats without ancestral gestational exposure did not 
develop polycystic ovaries (Manikkam et al., 2013). While these results indicate that such 
exposure contributes to a transgenerational establishment of PCOS in offspring, the study 
did not verify whether these effects were associated with the combined exposure to both 
phthalates and BPA, or to DBP exposure alone. Additionally, the dosage of exposure was 
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over 10,000 times the average daily human exposure encountered in the environment 
(Manikkam et al., 2013). However, in a study of reproductive-aged women that assessed 
serum phthalate levels, women with PCOS had significantly higher levels of DBP 
compared to controls (Xu, Lin, Zhao, & Zhang, 2011). Additionally, DBP levels were 
higher than any other phthalate concentration present in serum (Xu et al., 2011).  
Findings from prior research report that serum DBP levels positively correlate 
with serum E2 levels (X. Huang et al., 2007). As one of the principle estrogens, one of 
the primary actions of E2 is to stimulate the release of GnRH from the hypothalamus, 
which subsequently leads to increased secretion of LH. LH levels in women with PCOS 
are much higher compared to women without PCOS (Rotterdam, 2004). Additionally, 
administration of pharmacological analogs of E2 has been shown to induce PCOS-like 
characteristics in animal models (Brawer, Munoz, & Farookhi, 1986). In light of these 
results, the published research on DBP promotes further investigation. More specifically, 
additional animal studies should be conducted that exclusively assess the effects of 
gestational exposure to DBP at environmentally relevant exposure levels.  
 
Di(2-ethylhexyl)phthalate 
Di(2-ethylhexyl)phthalate is a common plasticizer used in the manufacturing of 
many consumer products such as wall coverings, floor tiles, food packaging, and 
furniture upholstery (Agency for Toxic Substances Disease Registry (ATSDR), 2002). 
Studies show that DEHP is a reproductive and developmental toxicant in humans and 
animals (Grande et al., 2007; Koch, Drexler, & Angerer, 2003; Lyche et al., 2009). The 
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current literature has produced conflicting findings in regard to the actions of DEHP on 
female reproduction. Prior animal studies have shown that DEHP exposure is associated 
with altered ovarian steroidogenesis and low levels of P, an endocrinological profile 
similar to PCOS cases (Davis, Maronpot, & Heindel, 1994). Furthermore, in vivo studies 
show that DEHP exposure decreases serum E2 levels, and stops ovulation in adult rats 
(Lovekamp-Swan & Davis, 2003). These actions are hypothesized to be carried out by 
the major metabolite of DEHP, mono(2-ethylhexyl) phthalate (MEHP), which has been 
proposed to directly inhibit ovarian production of E2, resulting in anovulation 
(Lovekamp-Swan & Davis, 2003). Polycystic ovaries also have been described in adult 
female rats after exposure to DEHP (Davis et al., 1994).  
Very few studies have examined the association between prenatal DEHP exposure 
and the development of PCOS. Overall, the results are conflicting with studies reporting 
that DEHP is negatively associated with PCOS incidence in offspring, and other studies 
reporting a positive association in offspring with PCOS-like symptoms and similar 
ovarian morphology. Indeed, the study conducted by Manikkam et al. (2013) mentioned 
in the previous section which included DEHP as one of the gestational phthalate 
exposures found an increased incidence of polycystic ovaries in F1 and F3 offspring 
(Figure 2). A study of gestational exposure to DEHP at environmentally relevant levels in 
mice found that the ovarian weights of female offspring were approximately 35% higher 
compared to offspring without prenatal DEHP exposure (Pocar et al., 2012). This finding 
correlates with the classical presentation of enlarged ovaries in PCOS cases (Chang, 
2014).  
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Conversely, phthalates have been shown to exert anti-androgenic effects in 
humans. A study conducted by Main et al. (2006) found that serum T concentration in 
infants was negatively associated with serum phthalate concentrations. In another human 
study, patients with relatively higher urinary concentrations of MEHP had lower odds of 
having PCOS in comparison to controls with normal levels of the metabolite (Vagi et al., 
2014). Additionally, the only cohort study known thus far to examine the impact of in 
utero phthalate exposure on PCOS development in offspring found that relatively higher 
maternal serum levels of phthalate metabolites, including MEHP, were associated with a 
lower prevalence of PCOS among their daughters (Hart et al., 2014). However, this study 
also found that maternal levels of another phthalate metabolite, mono-ethyl phthalate 
(MEP), were negatively associated with levels of AMH, a hormone secreted by maturing 
follicles to inhibit additional primordial follicle activation, in female offspring (Hart et 
al., 2014). These findings suggest that a decrease in AMH contributes to the increased 
activation of primordial follicles, potentially stimulating an alternative pathway of 
polycystic ovary development.	  As described previously, increased AMH levels have also 
been shown to be associated with PCOS. In regard to DEHP and MEHP, rodent studies 
have shown that they accelerate the rate of primordial follicle recruitment (Hannon & 
Flaws, 2015). Furthermore, DEHP was associated with an increased number of mature 
ovarian follicles (Hannon & Flaws, 2015). Classic PCOS cases exhibit an ovarian 
morphology consisting of many peripheral small antral follicles with relatively larger 
stroma compared to normal ovaries. Another characteristic distinctive of PCOS cases are 
an increased number of primary as well as preantral follicles (also termed secondary and 
	   37	  
tertiary follicles) (Hughesdon, 1982). Findings regarding the impact of DEHP exposure 
on follicle numbers, however, are also conflicting. While multiple animal studies have 
shown that DEHP exposure is associated with an increased number of preantral ovarian 
follicles, a number of other studies have shown that DEHP exposure is associated with 
decreases in both preantral and primary follicle numbers (Hannon & Flaws, 2015).  
The common morphologies exhibited in the polycystic ovary are a multitude of 
antral follicles encircled by a hyperplastic layer of theca cells, the primary source of 
androgen hyperproduction in the ovary. This hyperplastic layer arises from the 
dysregulated, increased secretion of LH (Chang, 2014). However, such morphology does 
not appear to be reflected in DEHP-exposed animals. In a recent study of in utero DEHP 
exposure in rats, the ovaries of exposed female offspring exhibited relatively thin theca 
cell layers relative to unexposed offspring (Meltzer, Martinez-Arguelles, Campioli, Lee, 
& Papadopoulos, 2014). In addition, exposure resulted in increased FSH levels, and no 
apparent changes in offspring fertility (Meltzer et al., 2014). Such findings imply that 
DEHP does not appear to be implicated in the pathogenesis of PCOS at the level of in 
utero exposure. However, the study was not able to accurately assess the levels of serum 
LH or the patterns of LH secretion in offspring. As increased levels of LH, along with a 
decreased periodicity of its secretion, are a hallmark of PCOS, additional studies are 
warranted.   
Given the discrepancies from the available literature, further animal studies are 
needed in order to better establish the effects of prenatal phthalate exposure on ovarian 
folliculogenesis in offspring. 
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Androgenic Endocrine Disruptors 
Hyperandrogenism is a hallmark feature of PCOS. Correspondingly, a multitude 
of research has shown that increased exposure to androgens in utero is associated with an 
increased incidence of PCOS in both animal and human studies. Aside from 
investigations on the impact of BPA, the role of endocrine disruptors in creating a 
hyperandrogenic environment for fetal exposure has not been well characterized in the 
literature. Overall, more endocrine disruptors have been found to exert anti-androgenic 
activity at the level of androgen receptors (ARs). However, some agents have been 
identified as potential androgenic endocrine disruptors. For example, a study conducted 
in women with PCOS by Cupisti et al. (2010) found that smokers had increased free T 
levels compared to nonsmokers. A study in rats has also shown that prenatal exposure to 
nicotine results in chronically increased levels of serum T in female offspring (Smith, 
Cloak, Poland, Torday, & Ross, 2003). The pathophysiology underlying the resultant 
increase in serum T has yet to be determined. However, studies suggest that the 
metabolism of nicotine by cytochrome P450 in the liver may have some effect on T 
biosynthesis in the liver, as this also involves cytochrome P450 family of proteins (Enea, 
Boisseau, Diaz, & Dugue, 2008; Ray, Tyndale, & Lerman, 2009). Another agent with 
androgenic activity is 3,4,4’-trichlorocarbanilide, also known as triclocarban (TCC). 
Triclocarban is an antimicrobial compound used in a variety of manufactured household 
and personal sanitizing products such as detergents, soaps, body washes, and cleansing 
lotions (Sapkota, Heidler, & Halden, 2007). Alone, TCC has little to no androgenic 
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activity; however, in the presence of T, TCC amplified the effects of T at the level of the 
AR by increasing AR-mediated transcriptional activity (Chen et al., 2008). Such a 
synergistic effect increases the bioactivity of endogenous T, implying a resulting 
physiological environment not unlike that created by increased serum androgen 
concentrations.  
 Numerous animal studies have successfully recreated a PCOS-like phenotype via 
gestational administration of excess androgens. In summary of what has been previously 
described, studies in female rhesus monkeys prenatally exposed to excess androgen had 
abnormal ovarian function, a later menarcheal onset, anovulatory cycling, impaired 
fertility, enlarged ovaries, as well as increased visceral fat distribution (Dumesic et al., 
1997; Eisner et al., 2002; Eisner et al., 2003). In addition to insulin resistance, these 
offspring also possessed an endocrinological profile similar to that of PCOS cases 
including hypersecretion of LH, and adrenal and ovarian androgens (Abbott et al., 2009). 
Furthermore, in rats, female offspring exposed to excess androgens in utero developed 
cystic ovarian follicles (Tehrani et al., 2014). The PCOS phenotype has also been 
recreated in sheep, with prenatally androgenized ewes meeting the diagnostic criteria for 
PCOS, in addition to having other abnormalities characteristic of PCOS including insulin 
resistance, LH hypersecretion and reduced negative feedback of P secretion 
(Padmanabhan & Veiga-Lopez, 2014).  
Additional research in animals has been conducted to better ascertain the effects 
of prenatal androgen exposure on female reproductive morphology and physiology. 
Studies have shown that the timing of in utero exposure to excess androgens may 
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critically impact whether PCOS manifests in adulthood. More specifically, the 
reproductive systems of female offspring with early fetal exposure were developmentally 
and morphologically abnormal relative to unexposed offspring, but hormonal physiology 
remained normal (Tehrani et al., 2014). Conversely, female offspring exposed during 
later stages of fetal development demonstrated abnormal hormonal profiles, yet 
maintained relatively normal reproductive system morphology (Tehrani et al., 2014). The 
authors indicated that the latter finding was more representative of classical PCOS cases. 
This assertion was supported by further results showing that the offspring with later fetal 
exposure had increased serum T concentrations, thereby indicating increased ovarian 
sensitivity to LH secretion (Tehrani et al., 2014). Additionally, this particular subset of 
offspring had decreased serum FSH and serum estrogen concentrations (Tehrani et al., 
2014). These results are consistent with findings from clinical studies as collected serum 
FSH concentrations are significantly lower in PCOS cases compared to normal women, 
indicating that PCOS is associated with decreased secretion of FSH during the early 
follicular phase of the menstrual cycle (Rebar et al., 1976).  
The pathophysiology responsible for decreased FSH secretion in PCOS remains 
to be characterized; however, studies have proposed that the negative feedback effect of 
chronically unopposed estrogen secretion could be the underlying mechanism involved 
(Chang, Mandel, Lu, & Judd, 1982; Yen, 1980). The reduction in serum FSH may also 
stem from the hypothalamic secretion of GnRH. More specifically, the increased 
frequency of pulsatile GnRH secretion could lead to a down-regulation of FSH gene 
expression and an up-regulation of LH gene expression, thereby potentially creating the 
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hormonal profile seen in prenatally androgenized rodents and PCOS cases alike (Chang, 
2014). Furthermore, it has been reported that a high pulse frequency of GnRH stimulates 
LH secretion whereas a low pulse frequency of GnRH secretion stimulates FSH secretion 
(Sullivan & Moenter, 2004). At the level of the hypothalamic regulation of GnRH 
secretion, a study in women with PCOS conducted by Eagleson et al. (2000) found that 
elevated plasma androgens decreased the sensitivity of the hypothalamic GnRH pulse 
generator to feedback inhibition by E2 and P. Interestingly, this sensitivity was restored 
when women were treated with an AR antagonist, flutamide (Eagleson et al., 2000). 
Findings of increased P and LH secretion as well as an increased frequency and 
amplitude of LH secretion in prenatally androgenized rats also imply a defect in feedback 
inhibition (Figure 3) (Wu et al., 2010).  
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Figure 4. Amplitude and Frequency of Luteinizing Hormone (LH) Secretion in 
Prenatally Androgenized Rats Compared to Controls. Rats were prenatally exposed 
from day 16 to 19 of gestation to 3 mg of either testosterone (pT) or dihydrotestosterone 
(pDHT). The amplitude and frequency of LH secretion measured between 60-70 days 
after birth over the span of two hours were higher in pT and pDHT rats compared to 
controls, which received no prenatal exposure. Data points are + the standard error of the 
mean. Taken from Wu et al., 2010.  
 
Taking into account the findings from Sullivan and Moenter (Sullivan & Moenter, 
2004), this decreased sensitivity and subsequent increase in GnRH pulse frequency may 
be responsible for the high levels of LH secretion, which subsequently stimulates 
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increased androgen production at the level of the theca cells in the ovary. The increases in 
androgen levels would result in decreased sensitivity of GnRH feedback inhibition, 
thereby implying the presence of a self-perpetuating pathophysiological cycle.  
The precise mechanism by which excess androgens alter hormonal physiology 
and induce fetal reprogramming remains to be understood; however the magnitude of 
effect is likely related to serum levels of plasma carrier proteins, particularly SHBG. 
Normally, approximately 98% of sex steroids in plasma are bound to carrier proteins 
derived from the liver. Plasma E2 and T (primarily) bind SHBG and albumin. 
Corticosteroid-binding globulin (CBG) binds cortisol, P, and a smaller percentage of 
plasma T compared to SHBG and albumin. Testosterone has a greater affinity for SHBG 
compared to E2; therefore, in women, SHBG binds to approximately 78% of T and only 
58% of E2 circulating in plasma (Chang, 2014). Albumin accounts for the remaining 
percentages of bound T and E2. As SHBG largely serves to prevent circulating sex 
steroids from entering target tissues, it strongly influences the amount of bioavailable sex 
steroids. Accordingly, increases or decreases in SHBG production can profoundly affect 
the magnitude of action by sex steroids as well as alter metabolism. In turn, prenatal 
androgen exposure has been shown to exert lifelong effects on genetic expression in the 
liver (Hammond, 2011).  
The role of SHBG in fetal development remains unclear; however, it is believed 
to protect female fetuses from androgen exposure and to control androgen action in male 
fetal sex differentiation (Hammond, 2011). In PCOS models represented by prenatally 
androgenized female rats, serum total T levels and free T index (i.e. the ratio of 
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circulating free T to circulating bound T) were higher compared to controls (Wu et al., 
2010). Reductions in SHBG may lead to significant hyperandrogenism in women. 
Clinical findings have shown that women presenting with hyperinsulinemia, excessive 
weight gain, or hyperandrogenism have also had decreased levels of circulating SHBG, 
and have subsequently gone on to develop hirsutism (Chang, 2014). Therefore, all of 
these conditions may be present at the same time in PCOS, thereby augmenting the 
effects of excess androgen production seen clinically. During development, prenatal 
exposure to excess T in ewes leads to hyperinsulinemia, which not only suggests that 
reprogramming takes place at the target tissues of insulin (i.e. liver, muscle, and adipose 
tissue), but also proposes the presence of a cyclical pathophysiology (Recabarren et al., 
2005). More specifically, excess androgen leads to hyperinsulinemia, which, in turn, may 
reduce levels of SHBG (Chang, 2014). Therefore, reduced levels of SHBG leads to 
excess androgen and thus hyperandrogenism. SHBG also appears to affect the 
hypothalamic-pituitary-ovarian axis. Indeed, reduced levels of SHBG resulting from 
hyperinsulinemia and hyperandrogenemia leads to increased levels of free E2, thereby 
enhancing its effect of feedback inhibition at the level of the hypothalamus. More 
specifically, increased E2 levels ultimately reduce the level of FSH secretion relative to 
LH secretion (Lebovic et al., 2005). 
Ovulatory dysfunction and menstrual disorders fall under the diagnostic criterion 
of oligo- or anovulation for PCOS (Rotterdam, 2004). This common PCOS feature has 
been replicated in animal models. Female rats with prenatal androgen exposure have been 
shown to develop irregular estrous cycles, have a decreased number of preovulatory 
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ovarian follicles, as well as have higher levels of LH and P (Wu et al., 2010). From these 
physiological findings, the authors confirmed that the prenatally exposed female rats had 
a significant reduction in ovulation in relation to unexposed female rats (Wu et al., 2010). 
The estrous cycles of the prenatally androgenized female mice were also longer 
compared to controls. Similar findings have also been reported in rhesus monkeys. 
Relative to female rhesus monkeys without prenatal exposure, female rhesus monkeys 
exposed to excessive androgens during the earlier or later stages of fetal life had 
ovulation dysfunction as well as decreases in menstrual cycle length by 40%-50% 
(Abbott et al., 2005). As these findings are analogous to the clinical presentations of 
PCOS patients, who have been shown to have reductions in ovulation and abnormal 
menstrual cycles, the hypothesized impact of excess androgen exposure during fetal life 
on the subsequent development of PCOS is further supported.  
The effect of excess androgens on progesterone receptor (PR) expression levels 
has been explored as a potential contributor to ovulatory dysfunction in PCOS. As 
previously described, during the follicular phase of normal hormonal cycling, the effect 
of feedback inhibition by P on GnRH pulse secretion progressively decreases, thereby 
resulting in a gradual increase in GnRH pulse secretion. Pulsatile secretion of GnRH 
continues to increase until it peaks late in the follicular phase. During that point in time, 
the rising levels of E2 secreted by the dominant ovarian follicle exerts a positive-
feedback effect on the already increased GnRH pulse generator, thereby stimulating 
increased LH secretion, otherwise known as the LH preovulatory surge. E2 and P 
produced and secreted from the corpus luteum following ovulation act to decrease GnRH 
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pulsatile frequency. This ultimately results in increased FSH secretion, which begins the 
next cycle of ovarian follicular development. It has been shown that the preovulatory 
peak in GnRH secretion responsible for the LH surge relies on the coupling of ovarian-
secreted E2 with a circadian neural signal (Chappell, Lee, & Levine, 2000; Wu et al., 
2010). Investigators have proposed that this coupling is negotiated by hypothalamic PR 
expression (Chappell et al., 2000). This hypothesis is supported by findings from rodent 
studies reporting that decreases or complete cessations (in PR knockout mice) of PR 
expression in the hypothalamus effectively prevent the E2-induced increase in GnRH 
pulsatility, and thus the LH surge (Chappell & Levine, 2000; Chappell et al., 1999). The 
same effect has also been demonstrated with the usage of a PR antagonist (Bellido, 
Gonzalez, Aguilar, & Sanchez-Criado, 1999). In addition to an association of higher 
levels of LH with oligoovulation, prenatally androgenized female rats have been reported 
to have decreases in hypothalamic PR expression in adulthood compared to unexposed 
female rats (Wu et al., 2010). Additionally, in both rats and mice, prenatal androgen 
excess was found to inhibit the LH surge by interfering with the positive feedback effect 
of rising E2, which also resulted in oligoovulation as well as anovulation (Moore, 
Prescott, & Campbell, 2013; Wu et al., 2010).  
The establishment of gonadotropin release that occurs during fetal and perinatal 
life in rats appears to follow a sexually dimorphic developmental pathway that is affected 
by the presence of androgens. A lack of androgen exposure will form a female brain, 
which will result in a cyclical pattern of preovulatory gonadotropin release maintained by 
hypothalamic regulation in adulthood. Conversely the presence of T will lead to the 
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development of a male brain, and thus will lack this adult cyclical pattern of secretion 
(Horvath, Cela, & van der Beek, 1998; Wu et al., 2010). Taking the findings reported by 
Wu et al. (2010) regarding decreased hypothalamic expression of PR in adulthood 
resulting from prenatal androgen exposure into account, it appears that this cyclical 
pattern of preovulatory gonadotropin secretion meant to be programmed during female 
fetal development was inhibited. Thus, exposure to excess androgens may induce fetal 
reprogramming, which ultimately results in anovulation in adulthood.  
However, the mechanism by which androgens suppress PR expression remains to 
be fully characterized. E2 has been observed to stimulate hypothalamic tissue-expression 
of PR (Foecking & Levine, 2005). However, in female mice, prenatal androgen exposure, 
and the resulting activation of AR, appear to inhibit PR generation by E2 (Foecking & 
Levine, 2005). The mechanism by which AR activation reprograms hypothalamic 
regulation that leads to the development of increased GnRH pulsatility in adulthood is 
still relatively unknown. Findings from studies in animal models propose potential 
mechanistic pathways. For example, synaptic connections to GnRH neurons in adult 
ewes that had excess prenatal androgen exposure have been shown to be markedly 
decreased compared to ewes without excess prenatal androgen exposure; however, the 
number of synaptic contacts were found to be comparable to those observed in adult 
males (Kim, Foster, & Wood, 1999).  These results appear to indicate that increased 
androgens may alter the synaptic activity of GnRH neurons by decreasing the number of 
synaptic connections. The reason behind the increased number of synaptic connections in 
normal females has yet to be identified. Therefore, it is unknown as to whether increased 
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synaptic connections confer an inhibitory effect thereby regulating GnRH secretion or 
enhance the preovulatory increase in GnRH. However, other studies have investigated the 
synaptic input to GnRH neurons from gamma aminobutyric acid (GABA) neurons as 
another target of AR activation.  
Previous studies have demonstrated that GnRH neurons are directly regulated by 
actions at a GABA A receptor (GABAAR) (Sullivan & Moenter, 2004). While GABA is 
known to exhibit an inhibitory effect on most neurons, this has not been verified in GnRH 
neurons at the level of GABAAR activation. However, in a study of female adult mice, 
those that had prenatal androgen exposure had an increased GABAergic drive to GnRH 
neurons as well as an increased level of GnRH response (determined by the relative 
frequency and size of post-synaptic GnRH current, respectively) to GABAAR activation 
compared to those that had no exposure (Sullivan & Moenter, 2004). Furthermore, 
evidence of the involvement of AR activation as administration of flutamide, an AR 
antagonist, to exposed female mice resulted in post-synaptic GnRH current frequencies 
and sizes that were similar to unexposed mice (Sullivan & Moenter, 2004). The efficacy 
of flutamide in restoring feedback inhibition of GnRH pulsatility by E2 and P in PCOS 
cases also implies that increased androgens have a role in the dysregulation of GnRH 
secretion (Eagleson et al., 2000). Despite these findings, further insight on the direct 
involvement of AR activation remains elusive as ARs are rarely found on GnRH neurons 
(Sullivan & Moenter, 2004). Therefore, further investigation on the presence and the 
potential role of AR in presynaptic GABA neurons is warranted.  
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While the published research using animal models largely indicate that fetal 
exposure to excess androgens contributes to PCOS development later in life, the literature 
of such exposure in humans is very limited and presents inconsistent findings. A major 
barrier in fully investigating this potential association is the lack of a safe method to 
quantify the level of human fetal exposure (Abbott & Bacha, 2013). Therefore, studies of 
prenatal exposure to excess androgen have been executed via indirect assessments or 
reviewing postnatal outcomes. The concentration level of androgens in umbilical cord 
blood has been used in multiple studies as an indirect assessment, but has produced 
mixed results. A study of female infants born to mothers with PCOS found that their 
blood concentrations of T in their umbilical veins were significantly higher compared to 
female infants born to mothers without PCOS (Barry et al., 2010). The gestational 
exposure presented in mothers with PCOS is not unlike exposure to excess androgen as 
increased maternal circulating levels of T are coming in contact with the fetal 
environment (Sir-Petermann et al., 2002). However, two studies have reported that PCOS 
gestation is associated with lower androgen concentrations in umbilical cord blood of 
female offspring (Anderson et al., 2010; Maliqueo et al., 2013). The limitations presented 
with cord blood collection may account for the mixed results. For example, investigators 
have proposed that the variable decreases in umbilical cord blood androgen 
concentrations that occur at the onset of labor may explain why elevated levels have not 
been observed in some studies (Abbott & Bacha, 2013). Another limitation with this 
indirect measurement is that umbilical cord blood of both fetal and maternal origin and 
collection at birth is outside the critical period of neural and ovarian differentiation in 
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humans (Padmanabhan, Veiga-Lopez, Abbott, & Dumesic, 2007). If the ovary is the 
target of excess androgen exposure with its differentiation occurring during midgestation, 
any potential hormonal abnormalities may not be present, and thus undetectable, at birth 
(Abbott & Bacha, 2013).  
In amniotic fluid analyses collected at midgestation, female fetuses of PCOS 
gestations had higher levels of T compared to female fetuses of mothers without PCOS 
(Palomba et al., 2012). Additionally, increased maternal T levels at midgestation have 
been shown to predict increased AMH levels in female offspring at adolescence, a 
clinical feature characteristic of both adolescents and adults with PCOS (Hart et al., 2010; 
Sir-Petermann et al., 2009). Increased AMH levels are also prevalent among infants born 
to mothers with PCOS (Crisosto et al., 2012; Sir-Petermann et al., 2012). While 
daughters born to women with PCOS have an increased risk of developing the syndrome 
as adults, the relevant literature has not yet found a relationship between midgestational 
androgen levels in female fetuses and the adulthood development of PCOS (Abbott & 
Bacha, 2013; Goodarzi, Dumesic, Chazenbalk, & Azziz, 2011). As with umbilical cord 
blood analyses, the timing of collection may account for the lack of association. In a 
prospective cohort study, investigators found no correlation between midgestational 
maternal blood concentration of androgens and the development of PCOS traits in female 
offspring during adolescence (Hickey et al., 2009). Gestational levels of T in male 
fetuses, however, are increased from about six to sixteen weeks of gestational age and 
subsequently decrease to a low level until birth (Rouiller-Fabre et al., 2009). Another 
study conducted by Fowler et al. (2011) reported that male fetal programming of 
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masculinization by androgen approximately occurs before eleven to thirteen weeks of 
gestation. As maternal blood collection occurred during the eighteenth week of gestation 
in the study by Hickey et al. (2009), fetal reprogramming and any potential abnormalities 
in hormonal levels may have already taken place and were no longer measurable 
(Padmanabhan & Veiga-Lopez, 2013). 
 Other investigators have proposed that excess androgen outside of fetal origin are 
unlikely to contribute to the development of PCOS in adulthood. During gestation, 
elevated levels of SHBG in maternal circulation and placental androgen metabolism 
effectively function to protect the fetal environment from excess exposure (Abbott, 
Dumesic, & Franks, 2002). However, this does not exclude endocrine disruptors, which 
may bypass or compromise maternal protection to the fetus. Of the previously discussed 
androgenic endocrine disruptors, TCC has been detected in umbilical cord plasma, and 
nicotine has been shown to cross the placental barrier and accumulate in amniotic fluid at 
a concentration 88% greater than in maternal plasma (Pycke et al., 2014; Wickstrom, 
2007).
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DISCUSSION 
  
This review has provided a comprehensive overview of the current literature on 
the role of prenatal exposure to endocrine disruptors in the development of PCOS. While 
PCOS itself has been subject to widespread investigation, there is a paucity of research 
that seeks to ascertain its etiology as well as its developmental origins. Multiple gene-
association studies have been conducted to characterize a potential genetic basis for 
PCOS; however, reported findings regarding genetic linkage have been mixed and no 
candidate gene has been characterized as a marker for the PCOS phenotype (Abbott et al., 
2005). The heterogeneity in the presentation of the PCOS phenotype in sibling studies 
has provided evidence in support of the contribution from environmental factors 
(Diamanti-Kandarakis, Kandarakis, & Legro, 2006). Indeed, endocrine disruptors have 
had a role in the etiology of many chronic and complex diseases such as obesity, 
NIDDM, and cardiovascular disease (Diamanti-Kandarakis et al., 2009). The present 
literature review examined three classes of endocrine disruptors and their potential 
involvement in the pathogenesis of PCOS beginning in fetal life. BPA, an agent 
commonly found in many plastics and other consumer products has been shown to have 
estrogenic activity. Indeed, BPA levels appear to be higher in women with PCOS 
(Kandaraki et al., 2011; Toru Takeuchi et al., 2004). Additionally, prenatal exposure to 
BPA in animal models was shown to increase GnRH as well as LH secretion in a 
hormonal profile similar to that seen in PCOS cases. Serum BPA levels were also 
positively associated with levels of free T and the severity of insulin resistance.  
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The review of phthalates included investigations on the influence of DBP and 
DEHP. Regarding DBP, its serum levels have also been reported to be higher in women 
with PCOS. Prenatal exposure to DBP, in conjunction with DEHP and BPA, resulted in 
an increased incidence of polycystic ovaries in F1 and F3 offspring. In animal models, 
DBP levels were also positively associated with levels of E2, which may account for the 
increases in GnRH and LH secretion seen in PCOS cases. Prenatal exposure to DEHP, a 
well-established reproductive and developmental toxicant, has been shown to decrease 
E2 levels, thereby inhibiting ovulation in animal models due to the lack of positive 
feedback on GnRH secretion. The findings reported from animal models remain 
controversial as human studies appear to be contradictory and show a decreased 
incidence of PCOS among daughters with phthalate exposure (Hart et al., 2014).  
While many studies have documented the effect of fetal exposure to excess 
androgen in creating a PCOS phenotype, the available research on specific endocrine 
disruptors with androgenic activity is severely limited. The present literature review 
discussed two potentially applicable endocrine disruptors: nicotine and TCC. Prenatal 
exposure to excess androgens in animal models has resulted in phenotypes that include 
abnormal ovarian function, delayed menarche, anovulatory cycling, fertility impairment, 
enlarged/polycystic ovaries, and visceral fat distribution. In a mechanism that remains to 
be characterized, it appears that excess androgens have a role in decreasing the sensitivity 
of GnRH feedback inhibition, leading to its unregulated, increased secretion and the 
associated increase in LH secretion. The proposed pathophysiological mechanisms in the 
setting of increased androgen exposure during fetal life imply that they are driven in a 
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self-perpetuating cycle. However, research involving human fetal exposure to excess 
androgens has yielded inconsistent results. A significant portion of this outcome may be 
due to limitations in data collection, as exposing a fetus to excess androgen is unethical 
and collecting biological samples of the fetal environment throughout the gestational 
period is unsafe. Therefore, investigators have had to rely on more indirect sources of 
exposure assessment.  
 In regard to future research, other endocrine disruptors may also have a role in 
PCOS development through fetal exposure. One example is organochlorine (OC), an 
agent commonly used in pesticides. Pesticides that were OC-based were used worldwide 
until they were banned in the 1970s. However, due to the relatively prolonged duration of 
enzymatic degradation and their hydrophobic properties, OCs have been detected in 
living organisms and have been shown to bioaccumulate over a span of years. As 
endocrine disruptors, OCs have been shown to exert estrogenic activity. Interestingly, 
adipose tissue concentrations of OCs have been found to be greater among women with 
breast cancer compared to women without breast cancer. Their role in the development of 
a PCOS phenotype is currently unknown. It is possible that the role of OCs in PCOS 
development could be similar to the actions of other estrogenic endocrine disruptors such 
as BPA.  
Additionally, as this area of research is still in its infancy, further investigations 
are necessary including studies to resolve currently discrepant findings, explore other 
pathways of biological influence, clarify mechanisms of action, and determine more 
effective methods of exposure and outcome assessment. Regarding the selection of 
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animal models, investigators may benefit from assessing the relative level of 
precociousness among potential animal subjects. Mammals that have completed sexual 
differentiation and have well-developed neural systems at birth (such as marmosets, 
rhesus monkeys, sheep, and guinea pigs) usually do not exhibit ovulatory dysfunction 
when they are exposed to androgen excess unless it occurs before birth (Wallen & Baum, 
2002). With altricial animal models such as rats, a larger proportion of overall brain 
development takes place during fetal development compared to precocial animals 
(Wallen & Baum, 2002). Use of altricial animals to study the fetal origins of PCOS may 
therefore be a less accurate model of pathophysiological development in response to fetal 
exposure, as the rate of maturation and rapid brain growth are relatively higher compared 
to precocious models (Wallen & Baum, 2002).  
In order to execute indirect measurements of exposure that are more accurate, 
future human studies should better characterize the critical periods in fetal development 
when fetal reprogramming is hypothesized to occur. Longitudinal cohort studies could 
show promise in efforts to analyze associations between fetal exposure to particular 
endocrine disruptors and the incidence of PCOS.  
 
Conclusion 
In consideration of the available literature, endocrine disruptors appear to have an 
etiological role in the development of PCOS at the level of fetal exposure. However, 
more research is required in order to gain a better understanding of how PCOS originates 
and the mechanisms of action that endocrine disruptors exert that potentially result in 
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hormonal dysregulation. Because they are ubiquitous in the modern living environment, 
endocrine disruptors could potentially pose one of the largest hazards to maternal and 
fetal health. Therefore, as PCOS is of the most common endocrine disorders in women, it 
is of great importance to better characterize this condition’s origins in an effort to 
introduce effective methods of prevention for the generations of tomorrow.  
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Senior Thesis Research, Advisor: Theresa Lee, PhD  
 
Chronobiology & Neuroendocrinology Laboratory, University of Michigan 
Ann Arbor, MI  Jun 2007–Aug 2008 
Undergraduate Research Assistant, Advisor: Theresa Lee PhD  
 
Cardioprotection Research Laboratory, University of Michigan  
Ann Arbor, MI  Sept 2006–Apr 2007 
Undergraduate Research Opportunity Program (UROP) Student  
 
MEDICALLY RELEVANT EXPERIENCES 
 
Korle-Bu Teaching Hospital 
Accra, Ghana, West Africa  Mar–Apr 2013 
Hospital Volunteer  
 
Beth Israel Deaconess Medical Center 
Boston, MA  Jan–Aug 2013 
Physician Shadowing  
 
VOLUNTEER EXPERIENCES 
 
Read to A Child – Boston  
Boston, MA  Mar 2011–Jun 2013 
Reading and Mentoring Program Volunteer  
 
Washtenaw County American Red Cross Club  
Ann Arbor, MI  Sep 2006–Apr 2009 
American Red Cross Club Member and Committee Chair  
 
HONORS, AWARDS, SCHOLARSHIPS & FELLOWSHIPS 
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William C. Dement Behavioral Sciences Research Fellowship Program  
May 2009–Aug 2009 
 
Neuroscience Honors Senior Thesis Program, University of Michigan  
Jan 2009–May 2009 
 
Student Recognition Award, University of Michigan  
May 2005–May 2009 
Full- tuition scholarship recipient 
 
SKILLS 
 
Administrative 
● Experience with reviewing and developing case report forms (CRFs), serious 
adverse event (SAE) forms, participant contact, and taking inventory of study 
supplies. 
 
● Proficient in assembling research grants and proposals.  
 
Laboratory 
● Small animal handling experience with rodents including injections, blood 
collection, anesthesia, and cranial surgery techniques.  
 
● Trained polysomnography technician 
 
● Knowledgeable with using SAS and SPSS.  
 
● Proficient with multiple types of sleep diagnostic software including ActiView, 
ICELUS, Pursuit Sleep, EncorePro 2. Complete training in Compumedics 
software. 
 
HOBBIES	  
● Rock climbing, running, tennis, sailing, and figure skating.	  	  
